Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis

NEW YORK, NY, USA, November 8, 2019 / — Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in diagnosis of cognitive disorders, announced today initial enrollment of subjects participating in an IRB approved study to develop an Artificial Intelligence (AI) biomarker of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conducted at the Pacific Neuroscience Institute Brain Health Center (PBHC), an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA, this study is utilizing Evoke’s flagship medical device, the eVox® System.

The eVox System is commercially available and used by primary and specialty care physicians to aid in diagnosis of memory loss and other cognitive disorders such as Alzheimer’s disease. In the ongoing study, eVox will be used to collect computational electroencephalography (EEG) and event-related potentials (ERP) metrics for 300 patients with cognitive impairment. Data from these patients will be used together with Evoke’s existing database of over 55,000 standardized patient brain scans in order to train a novel end-to-end machine learning algorithm and develop a diagnostic digital signature of AD. The resulting AI biomarker is intended to provide rapid, sensitive, and specific diagnosis of MCI and AD in a primary care setting, thereby accelerating next-level care in disease detection and treatment planning.

“Alzheimer’s represents one of the most important public health concerns to affect us in the coming decades,” explains Dr. David Merrill, MD, PhD, PBHC director and geriatric psychiatrist, and study co-Principle Investigator. “Although currently no cure exists for Alzheimer’s, one in three cases of dementia could be prevented by addressing various lifestyle factors. But the key to prevention is recognizing brain changes related to cognitive decline as early as possible so physicians have adequate time to implement successful interventions.”

As the size and proportion of the U.S. population age 65 and older continue to increase, the number of Americans with Alzheimer’s or other dementias is anticipated to grow from 55 million in 2019 to 88 million by 2050. Delaying symptom onset by as little as 1 year could potentially lower AD prevalence by more than 9 million cases over the next 40 years. Thus, there is a need for sensitive and specific diagnostic tools to facilitate the early recognition of individuals at risk of dementia, who potentially can benefit from preventive interventions capable of postponing or avoiding the onset of this severe and disabling cognitive disorder.

“Our goal is to eradicate Alzheimer’s disease, and the first step towards that goal is establishing a precise diagnostic algorithm for AD detection,” said Dr. Morgan Ingemanson, PhD, Director of Medical Affairs at Evoke Neuroscience and study co-Principle Investigator. “We are thrilled to have begun data collection on what we anticipate to be a pivotal study in the AD digital diagnostics space. This milestone represents our continued commitment to providing the clinical community with critical tools to help diagnose patients with cognitive decline, and we are incredibly optimistic about pairing patient data collected at PBHC together with our vast existing EEG database in order to develop an AD digital signature. It has the potential to revolutionize the current gold standard in Alzheimer’s diagnosis.”

About Pacific Brain Health Center
Pacific Neuroscience Institute Brain Health Center (PBHC, is an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA specifically focused on the diagnosis and treatment of patients with subjective cognitive impairments (SCI), mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other dementias. The PBHC has assembled a highly experienced team of full-time specialists, all previously esteemed researchers and clinicians from UCLA and UCSD specializing in neurology, psychiatry, cognitive psychology, neuroscience and geriatric medicine.

About Evoke Neuroscience:
Evoke Neuroscience ( was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Primary and specialty care physicians can use eVox® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

Evoke Neuroscience takes on TBI, PTSD with the US Air Force

NEW YORK CITY, NY, USA, September 10, 2019 / — Evoke Neuroscience has been awarded a working contract by the United States Air Force (USAF) for its diagnostic device, the eVox® System.

The contract is part of the USAF Small Business Innovation Research (SBIR) Phase I program that provides the framework for a fully integrated solution with Air Force constituents.

Timely diagnosis of military personnel with mTBI, stress-related conditions, PTSD, and related memory loss or cognitive symptoms is critical and brain-based biomarkers can help. The eVox® System is a medical device that acquires computational EEG/ERP biomarkers to provide automated, objective, and non-invasive measurements of brain function to aid in diagnosis. The contract award enables the Air Force to acquire and evaluate eVox specifically for use cases with USAF stakeholders.

Air Force Research Lab (AFRL) and AFWERX have partnered to streamline the SBIR process in an attempt to speed up the experience, broaden the pool of potential applicants, and decrease bureaucratic overhead. Beginning in SBIR 18.2, and now in 19.2, the Air Force has begun offering ‘Special’ SBIR topics that are faster, leaner and open to a broader range of innovations.

“For the last 5 years, eVox has been used to support the mental health and medical care of U.S. Military personnel,” explains Marinela Gombosev, Evoke Neuroscience CEO. “Through this AFWERX SBIR Phase I contract award, we look forward to expanding access to objective biomarkers of brain function to Air Force service members who are deserving of the best available tools and medical care.”

At the conclusion of Phase I, Evoke will present a plan to deploy its technology -identifying USAF opportunities with the most critical need and highest potential benefit -for a subsequent AFWERX SBIR Phase II contract award.

This contract award expands upon Evoke Neuroscience’s government contract portfolio which includes a Veterans Health Administration Contract for the eVox® System (#36F79718D0348), that enables the VA and other federal organizations to purchase the eVox System at pre-approved pricing via the Veterans Administration’s FSS Contract, via GSA Advantage, or GSA eBUY.

About Evoke Neuroscience, Inc.

Evoke Neuroscience ( was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.

Evoke Neuroscience named to Inc. 5000 List of America’s Fastest-Growing Private Companies for Second Consecutive Year

For the second consecutive year, Evoke Neuroscience was ranked on Inc. magazine’s annual Inc. 500|5000, an exclusive list of the nation’s fastest- growing private companies. Market leader in brain assessment and training technology, Evoke Neuroscience was recognized in 2017 for achieving an impressive three-year growth rate of 537%.

“Evoke Neuroscience is honored to be named to the Inc. 5000 list for the second consecutive year,” said Evoke Neuroscience CEO and co-founder, David Hagedorn, PhD. “To be included in this list is a significant achievement for Evoke and we are proud to be recognized for doing our part to spur innovation, create jobs, and drive the economy forward.”

On average, the 2017 Inc. 5000 honorees achieved a three-year average growth of 481%. The companies boast an aggregate revenue of $206 billion and collectively generated 619,500 jobs over the past three years.

“We believe that everyone should have access to affordable and easy-to-use tools that measure and train brain health. Evoke’s clinical solutions are making this dream a reality for patients throughout the country – from patients with cognitive concerns to elite athlete peak performance training and the military, including the US Special Operations Forces.” Evoke Neuroscience co-founder and Chief Strategy Officer, James Thompson, PhD, explained. “Our steady, consistent growth as a company fortifies our mission to improve patient health and quality of life by bringing medical neuroscience out of the laboratory and into the physician’s office.”

Learn more about Evoke Neuroscience’s state-of-the-art hardware/software system that objectively measures and trains the brain. For more information, contact Evoke Neuroscience at

About Evoke Neuroscience

Evoke Neuroscience ( was formed in 2009 by research scientists, clinicians, medical doctors, and business professionals dedicated to developing and delivering the most important advances in brain science. Evoke Neuroscience believes that improving patient health starts with the brain. Their flagship product, the eVox® System, is an accessible, affordable, and easy to use tool that empowers primary and specialty care physicians to objectively measure and train the brain.

About Inc.

The Inc. 5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment— its independent small and midsized businesses. Companies such as GoPro, Oracle, Square, Timberland, Microsoft, Dell, Pandora, Timberland, and many other well-known names gained their first national exposure as honorees of the Inc. 5000.

Inc. 500|5000 Methodology

The 2017 Inc. 5000 is ranked according to percentage revenue growth when comparing 2013 to 2016. To qualify, companies must have been founded and generating revenue by March 31, 2013. They had to be U.S.-based, privately held, for profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2016. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2013 is $100,000; the minimum for 2016 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Companies on the Inc. 500 are featured in Inc.’s September issue. They represent the top tier of the Inc. 5000, which can be found at

Medical brain tech company Evoke Neuroscience ranked by Inc. 500 as one of America’s fastest growing companies

Inc. magazine ranked Evoke Neuroscience No. 131 on its Inc. 500, an exclusive ranking of the nation’s fastest-growing private companies. Market leader in brain assessment and training, Evoke Neuroscience made the list by achieving a three-year growth rate of 2,638%.

“This recognition fortifies our mission to improve health and quality of life with cognitive improvement tools that are accessible, affordable, and easy to use. We are proud to be recognized for doing our part to spur innovation, create jobs, and drive the economy forward,” said David Hagedorn, PhD, co-founder and CEO. “We share this honor with our loyal customers, dedicated partners and talented employees.”

As a 2016 honoree, Evoke Neuroscience now shares a pedigree with GoPro, Oracle, Zappos, Square, Timberland, and other notable alumni that gained early exposure as members of the Inc. 500.

Evoke Neuroscience co-founder and Chief Strategy Officer James Thompson, PhD, attributes the company’s success to a passion for making medical neuroscience easily accessible. “We believe that everyone should have access to tools that gauge and improve their brain health and function. Evoke’s clinical solutions help patients with a variety of cognitive concerns. But they extend far beyond the physician’s office – from peak performance training of elite athletes to the military, including the US Special Operations Forces.”

Inc. unveiled its 35th annual Inc. 5000, with the top 500 companies also featured in the Inc. 500 and the September issue of Inc. magazine. Collectively, this year’s top 500 companies have created more than 55,000 jobs, earned $13.8B total revenue, and achieved an impressive median three-year growth rate of 1,581%.

About Evoke Neuroscience
Evoke Neuroscience ( was formed in 2009 by research scientists, clinicians, medical doctors, and business professionals dedicated to developing and delivering the most important advances in brain science. Evoke Neuroscience’s goal is to improve people’s health, performance, and quality of life with cognitive tools that are accessible, affordable, and easy to use.

About Inc. 500|5000 List
The Inc. 500|5000 List showcases the fastest growing, privately-held companies in America. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. Companies are ranked according to the percentage growth of their annual revenue over a 3 year period; the 2016 Inc. 5000 is ranked according to percentage revenue growth when comparing 2012 to 2015. Complete results of the Inc. 500|5000 can be found at

Evoke Neuroscience recognized as key innovator in advancing transformative technology for mental wellbeing


Evoke Neuroscience has been featured in the first-ever TransTech 200 list for advancing technology for mental and emotional wellbeing. TransTech 200, curated by the Transformative Technology Lab, is the first list to highlight pivotal innovators, influencers, organizations, scientists, and entrepreneurs who are expanding the known limits of human thriving.  “We are grateful to be recognized for the work we do in the space,” said David Hagedorn, Ph.D., Evoke Neuroscience co-founder and CEO. “We are honored that our effort to bring functional neuroimaging to the physician’s office in an easy-to-use, objective, and cost-effective way is recognized as innovative and influential. Our focus is on improving human health and wellbeing, and that starts with the brain.” Awarded for innovation in the category of Neurofeedback, Evoke Neuroscience creates cutting edge technology that allows physicians to evaluate patient brain health and to train the brain in order to achieve healthier functioning. As a TransTech honoree, Evoke Neuroscience now shares a pedigree with DARPA, Google, Fitbit, HeartMath, and other notable companies and scientists on the 2016 list.

About Evoke Neuroscience
Evoke Neuroscience was formed in 2009 by research scientists, clinicians, medical doctors, and business professionals dedicated to developing and delivering the most important advances in brain science. Evoke Neuroscience’s goal is to improve people’s health, performance, and quality of life with cognitive tools that are accessible, afordable, and easy to use.

About TransTech 200 List
The TransTech 200 is the annual list of the key innovators who are driving technology for mental and emotional wellbeing forward. The list is open to both individuals and organizations who are making significant contributions via Transformative Technology research, creation, and/or distribution. Complete results of the TransTech 200 can be found at

How biofeedback games can rewire your brain.

The US has seen an increase in conditions that impact brain health; 48% of Veterans returning from combat who seek VA treatment are diagnosed with a mental health problem. The rate of reported sports-related concussions has doubled in the past decade. And diagnoses for neurological disorders such as ADHD and dementia have been steadily increasing.

Though there are cases in which medication is absolutely necessary, there are growing concerns about the rapid rise and abuse of psychotropic prescriptions without a proper evaluation by a mental health professional. Dr. James Thompson of Evoke Neuroscience spoke to Hopes&Fears about how biofeedback training can help rehabilitate the physiological changes resulting from traumatic brain injuries.

A physiological approach

In 2009, Doctors James Thompson and David Hagedorn founded Evoke Neuroscience with exactly this goal in mind. Specializing in traumatic brain injuries caused by sports injury and military trauma respectively, both Thompson and Hagedorn were using electrophysiology as a measurement tool to see how the injury was affecting brainwaves and heart rate patterns and figure out how they could recover normal functioning. “A lot of medications deal with symptoms [of traumatic brain injury] but aren’t actually treating the root causes of the symptoms,” Dr. Thompson tells Hopes&Fears. “The anxiety, the depression, the sleep disorders—they’re all a result of physiological changes in your brain.”

Medication can provide supplementation or re-uptake certain chemicals that cause these symptoms, but take away the medication and the chemical processes still haven’t been cured. Instead, Evoke uses brain processing speed measures, cardiac measures and neuropsychological testing to target parts of the brain which aren’t functioning properly, and then uses neurofeedback to train the neurons back to health. “By doing EEG neurofeedback training, you’re teaching the neurons to release chemicals and to communicate in specific patterns. And by reinforcing those patterns, the neurons actually learn to communicate in a process called long-term potentiation,” Thompson explains. “The saying is, ‘the neurons that fire together, wire together.’”

The problem, Thompson says, is that this information is hard to collect, requiring data collection using multiple measurement systems and hours of cross-specialty analysis. So while neurofeedback and heart rate variability (HRV) training have been shown in a multitude of peer reviewed literature publications to be effective in remediation the negative effects of central and autonomic nervous system trauma such as concussion and PTSD, the roadblocks in knowledge and access keep physicians from practicing them. What Evoke has developed is a system that puts all of the software, hardware and education in one accessible, easy-to-use place. “We thought, ‘wouldn’t it be cool to get access to this type of information to more practitioners?’” Thompson recalls. “Instead of two hours just to collect the data, our system can do it in just 20 minutes.”

The Evoke team also provides a multifaceted education program with training manuals, bi-monthly live webinars and over 250 research references so that doctors can read the original studies behind specific parts of their tools. “It’s like a specified internet,” Thompson jokes, “we brought all the information together so they don’t have to go searching for multiple hours.”

How it works

The Evoke system is a portable brain-computer interface that allows physicians to assess the extent and specific locations of brain injury by conducting EEG readings using a special device fondly called the “Michael Phelps” due to its swim cap-like appearance. Heart and breath rate are also measured, giving the physician a full picture of a patient’s central and autonomic nervous systems. With a report in hand, the physician can create a training program that targets those specific brain areas that are not performing optimally to get them to “fire and wire” together. “When the neurons in those regions start firing the way we want them to, the person gets rewarded by an auditory sound or visual cue that basically says, ‘good job,'” Thompson explains, “by getting that reward, chemicals are released and the neurons learn to uptake those chemicals, which is reinforced by doing the training over and over again.”

Take your typical concussion patient. Traditionally, related symptoms such as chronic headaches and sleep disorders are treated using medication with hopes that patients can cope with the symptoms long enough for the concussion to resolve itself. But with Evoke’s system, a doctor can identify the physiological problems and prescribe treatment that actually resolves the functional damage caused by the concussion. So if the patient is experiencing sudden difficulty with their emotional regulation, for instance, a doctor can check for frontal lobe functionality, which deals with emotional regulation, and assess whether it’s functioning optimally. Or if the patient is complaining of headaches, a physician can measure heart rate variability which, when unbalanced, can affect blood flow, thus causing headaches. With this information, a physician can target neurofeedback training to the frontal lobe or set up an HRV program to re-regulate blood flow. Combined with proper medications and supplements, the Evoke system rounds off a holistic approach toward rehabilitation.

Typically patients will do neurofeedback training an average of three days a week, in about twenty to forty sessions running about 30 minutes each. “Your brain is plastic, meaning it can change,” Thompson explains, “by training it and exercising your brain it literally changes to meet the criteria you set for it. So in training, your brain is learning the patterns that are more normal.” Patients are also provided with a wristband and training app that goes home with them so they can train between scheduled doctor’s visits, much like the prescription model that practitioners are already used to.

Tried, tested and true

The spectrum of patients who can benefit from biofeedback training is remarkably broad, from young people with ADHD, to athletes with sports injuries, to professionals working in high-stress environments suffering from crippling anxiety and sleep disorders as a result. Physicians using Evoke’s technology also see a lot of Veterans suffering from psychophysiological disorders resulting from PTSD, as well as older people experiencing mild cognitive impairment that comes naturally with age or who use HRV rehabilitation after a cardiac event. “There’s a lot of research demonstrating a significant reduction in the likelihood of a second heart attack if you do HRV training after your first heart attack,” Thompson points out.

Though Evoke is in no way proposing that biofeedback training can completely replace medication, there is no doubt that the system is an effective rehabilitation tool. “In terms of whether the technology we’re developing is going to be helpful, we know that it will. We didn’t invent HRV training or brainwave analysis or neurofeedback,” notes Thompson. “Those all existed already; brainwave patterns were discovered in 1924 by Hans Berger. Neurofeedback and the ability to train specific patterns and change brain functioning has been around since the 1960s. We didn’t invent anything. All we did was make it accessible, easy and understandable.”

Untangling Alzheimer’s: Simple lifestyle changes may prevent cognitive decline

Majid Fotuhi built his First brain out of wood and foam. It was the best way, he thought, to help his fellow students at Harvard grasp how complex and beautiful the organ is. Fotuhi hired a pair of art-school students for the summer of 1993, and millimeters at a time, they sketched a dead human’s brain that Fotuhi schlepped back and forth between the neuroanatomy lab and the art studio across campus.